Citigroup
PYXS icon

Citigroup’s Pyxis Oncology PYXS Stock Holding History

Citigroup’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54K Sell
1,740
-1,162
-40% -$1.75K ﹤0.01% 5396
2025
Q4 		$3.34K Buy
2,902
+1,621
+127% +$5.72K ﹤0.01% 5356
2025
Q3 		$2.84K Sell
1,281
-7,646
-86% -$11K ﹤0.01% 5403
2025
Q2 		$9.82K Sell
8,927
-26,113
-75% -$29.4K ﹤0.01% 5190
2025
Q1 		$34.3K Sell
35,040
-7,048
-17% -$9.4K ﹤0.01% 4984
2024
Q4 		$65.7K Buy
42,088
+6,513
+18% +$18.8K ﹤0.01% 5002
2024
Q3 		$131K Buy
35,575
+24,613
+225% +$86.1K ﹤0.01% 4630
2024
Q2 		$36.3K Sell
10,962
-33,733
-75% -$142K ﹤0.01% 4766
2024
Q1 		$190K Buy
+44,695
New +$188K ﹤0.01% 4046
2023
Q1 		– Sell
-357,537
Closed -$479K – 5787
2022
Q4 		$479K Buy
357,537
+45,229
+14% +$67.9K ﹤0.01% 3207
2022
Q3 		$615K Sell
312,308
-103
-0% -$269 ﹤0.01% 3088
2022
Q2 		$744K Buy
312,411
+79,282
+34% +$211K ﹤0.01% 2917
2022
Q1 		$942K Buy
233,129
+229,923
+7,172% +$1.68M ﹤0.01% 3028
2021
Q4 		$35K Buy
+3,206
New +$36.7K ﹤0.01% 5224

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's PYXS Position: Q1 2026 in Review

Citigroup reduced its Pyxis Oncology (PYXS) stake by 40% in Q1 2026, selling an estimated $1.75K and leaving 1,740 shares worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #5396.

Citigroup first reported a position in PYXS in Q4 2021 and has held it in 14 quarters since. The position peaked at $942K in Q1 2022. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Citigroup held 1,740 shares of Pyxis Oncology worth $2.54K as of Q1 2026.
  • Citigroup sold 1,162 Pyxis Oncology shares in Q1 2026, an estimated $1.75K.
  • Pyxis Oncology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5396 holding.
  • Citigroup first reported a position in Pyxis Oncology in Q4 2021 and has held it in 14 quarters since.
  • Citigroup's Pyxis Oncology position peaked at $942K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.